NCT01825395Approved For Marketing不适用
Use of 3,4-Diaminopyridine(3 4-DAP)in the Treatment of Lambert-Eaton Syndrome (LEMS)
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- Approved For Marketing
- 试验地点
- 1
研究概览
简要总结
To learn more about the effect of 3, 4-Diaminopyridine (3,4-DAP) on patient diagnosed with Lambert-Eaton myasthenic syndrome (LEMS).
研究设计
- 研究类型
- Expanded Access
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age 18 years or older,
- •Diagnosed with LEMS,
- •If female, have a negative pregnancy test, and
- •If premenopausal, be willing to practice an effective form of birth control during the study,
- •Tested and found by ECG not to have a prolonged QT syndrome,
- •Agree to have a second ECG at the time of peak drug effect,
- •Has understood and signed the Informed Consent.
排除标准
- •Is known to have a sensitivity to 3, 4-DAP,
- •Has a history of:
- •past or current seizures,
- •cardiac arrhythmia,
- •hepatic, renal or hematologic disease, or
- •severe asthma,
- •Is believed by the investigator to be unable to comply with the protocol.
研究者
研究点 (1)
Loading locations...
相似试验
No Longer Available
不适用
Treatment of Lambert-Eaton Syndrome With 3,4 DiaminopyridineLambert-Eaton Myasthenic SyndromeNCT00994916David Lacomis, MD
No Longer Available
不适用
Treatment of Lambert-Eaton Syndrome With 3,4 DAPLambert Eaton Myasthenic SyndromeNCT00704925David P. Richman, MD
No Longer Available
不适用
Use Of 3,4-Diaminopyridine (3,4-DAP) In The Treatment Of Lambert Eaton Myasthenic SyndromeLambert-Eaton Myasthenic SyndromeNCT01373333The Cleveland Clinic
已完成
不适用
Randomized Study of 3,4-Diaminopyridine for Lambert-Eaton Myasthenic SyndromeLambert-Eaton Myasthenic SyndromeNCT00004832FDA Office of Orphan Products Development26
Approved For Marketing
不适用
3,4-Diaminopyridine Use in Lambert-Eaton Myasthenic Syndrome(LEMS) and Congenital Myasthenic Syndromes (CMS)Lambert-Eaton Myasthenic SyndromeCongenital Myasthenic SyndromeNCT00872950Lahey Clinic